BR9910505A - Terapia de combinação compreendendo ribavirina e interferon alfa em pacientes cândidos de tratamento antiviral tendo infecção crÈnica por hepatite c - Google Patents

Terapia de combinação compreendendo ribavirina e interferon alfa em pacientes cândidos de tratamento antiviral tendo infecção crÈnica por hepatite c

Info

Publication number
BR9910505A
BR9910505A BR9910505-5A BR9910505A BR9910505A BR 9910505 A BR9910505 A BR 9910505A BR 9910505 A BR9910505 A BR 9910505A BR 9910505 A BR9910505 A BR 9910505A
Authority
BR
Brazil
Prior art keywords
ribavirin
candid
infection
combination therapy
chronic hepatitis
Prior art date
Application number
BR9910505-5A
Other languages
English (en)
Portuguese (pt)
Inventor
Janice K Albrecht
Original Assignee
Schering Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=22151354&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=BR9910505(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Schering Corp filed Critical Schering Corp
Publication of BR9910505A publication Critical patent/BR9910505A/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/21—Interferons [IFN]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/21—Interferons [IFN]
    • A61K38/212—IFN-alpha
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Virology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Molecular Biology (AREA)
  • Zoology (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Epidemiology (AREA)
  • Pulmonology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
BR9910505-5A 1998-05-15 1999-05-13 Terapia de combinação compreendendo ribavirina e interferon alfa em pacientes cândidos de tratamento antiviral tendo infecção crÈnica por hepatite c BR9910505A (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US7956698A 1998-05-15 1998-05-15
PCT/US1999/007037 WO1999059621A1 (en) 1998-05-15 1999-05-13 Combination therapy comprising ribavirin and interferon alpha in antiviral treatment naive patients having g chronic hepatitis c infection

Publications (1)

Publication Number Publication Date
BR9910505A true BR9910505A (pt) 2001-01-02

Family

ID=22151354

Family Applications (1)

Application Number Title Priority Date Filing Date
BR9910505-5A BR9910505A (pt) 1998-05-15 1999-05-13 Terapia de combinação compreendendo ribavirina e interferon alfa em pacientes cândidos de tratamento antiviral tendo infecção crÈnica por hepatite c

Country Status (22)

Country Link
EP (3) EP1213029A1 (enExample)
JP (2) JP5281726B2 (enExample)
KR (1) KR100694345B1 (enExample)
CN (1) CN1230198C (enExample)
AR (1) AR019551A1 (enExample)
AT (1) ATE216591T1 (enExample)
AU (2) AU766597B2 (enExample)
BR (1) BR9910505A (enExample)
CA (1) CA2331823A1 (enExample)
CZ (1) CZ300540B6 (enExample)
DE (1) DE69901321T2 (enExample)
DK (1) DK0956861T3 (enExample)
ES (1) ES2172288T3 (enExample)
HU (1) HU230432B1 (enExample)
IL (3) IL139220A0 (enExample)
MY (1) MY129244A (enExample)
NO (1) NO330715B1 (enExample)
NZ (1) NZ507621A (enExample)
PT (1) PT956861E (enExample)
SK (1) SK288038B6 (enExample)
TW (1) TWI277424B (enExample)
WO (1) WO1999059621A1 (enExample)

Families Citing this family (47)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2686899B1 (fr) 1992-01-31 1995-09-01 Rhone Poulenc Rorer Sa Nouveaux polypeptides biologiquement actifs, leur preparation et compositions pharmaceutiques les contenant.
WO2000037110A2 (en) * 1998-12-18 2000-06-29 Schering Corporation Ribavirin-pegylated interferon alfa induction hcv combination therapy
BR0016162A (pt) * 1999-12-23 2002-08-13 Ribapharm Composições e métodos para l-nucleosìdeos, lnucleotìdeos e seus análogos
JP4536194B2 (ja) * 2000-02-17 2010-09-01 大日本住友製薬株式会社 安定な注射用製剤
AU2001261024A1 (en) 2000-04-12 2001-10-30 Delta Biotechnology Limited Albumin fusion proteins
MY164523A (en) 2000-05-23 2017-12-29 Univ Degli Studi Cagliari Methods and compositions for treating hepatitis c virus
CA2410579C (en) 2000-05-26 2010-04-20 Jean-Pierre Sommadossi Methods and compositions for treating flaviviruses and pestiviruses
AU2002213343A1 (en) * 2000-10-18 2002-04-29 Schering Corporation Ribavirin-pegylated interferon alfa HCV combination therapy
AU2002330154A1 (en) 2001-09-28 2003-04-07 Centre National De La Recherche Scientifique Methods and compositions for treating hepatitis c virus using 4'-modified nucleosides
EP1536839B1 (en) * 2001-11-09 2010-09-15 Intarcia Therapeutics, Inc Combination therapy comprising omega-interferon for treating infection with hepatitis c virus or yellow fever virus
EP2277910A1 (en) 2001-12-21 2011-01-26 Human Genome Sciences, Inc. Albumin fusion proteins
US7608600B2 (en) 2002-06-28 2009-10-27 Idenix Pharmaceuticals, Inc. Modified 2′ and 3′-nucleoside prodrugs for treating Flaviviridae infections
CN101172993A (zh) 2002-06-28 2008-05-07 埃迪尼克斯(开曼)有限公司 用于治疗黄病毒感染的2′－c－甲基－3′－o－l－缬氨酸酯核糖呋喃基胞苷
CN1678326A (zh) 2002-06-28 2005-10-05 埃迪尼克斯(开曼)有限公司 用于治疗黄病毒感染的2'－c－甲基－3'－o－l－缬氨酸酯核糖呋喃基胞苷
RS114004A (sr) 2002-06-28 2007-02-05 Idenix (Cayman) Limited, Modifikovani 2'i 3'-nukleozid prolekovi za lečenje flaviridae infekcija
JP2006519753A (ja) 2002-11-15 2006-08-31 イデニクス（ケイマン）リミテツド ２’−分枝ヌクレオシドおよびフラビウイルス科ウイルス突然変異
MXPA05006230A (es) 2002-12-12 2005-09-20 Idenix Cayman Ltd Proceso para la produccion de nucleosidos ramificados-2'.
EP1594530A4 (en) 2003-01-22 2006-10-11 Human Genome Sciences Inc HYBRID PROTEINS OF ALBUMIN
CA2529311A1 (en) * 2003-03-28 2004-10-07 Pharmasset, Inc. Compounds for the treatment of flaviviridae infections
CA2520148A1 (en) * 2003-04-01 2004-12-23 Intermune, Inc. Compositions and methods for treating coronavirus infection and sars
CN1798572A (zh) * 2003-04-17 2006-07-05 阿雷斯贸易股份有限公司 用于严重急性呼吸道综合征(SARS)的干扰素β
PL3521297T3 (pl) 2003-05-30 2022-04-04 Gilead Pharmasset Llc Zmodyfikowane fluorowane analogi nukleozydów
US7482149B2 (en) * 2003-06-09 2009-01-27 Genome Institute Of Singapore Inhibition of SARS coronavirus infection with clinically approved antiviral drugs
US20070202078A1 (en) * 2003-08-13 2007-08-30 Smith Howard J Method Of Treating Viral Infections
AR045870A1 (es) * 2003-10-11 2005-11-16 Vertex Pharma Terapia de combinacion para la infeccion de virus de hepatitis c
CN101023094B (zh) 2004-07-21 2011-05-18 法莫赛特股份有限公司 烷基取代的2-脱氧-2-氟代-d-呋喃核糖基嘧啶和嘌呤及其衍生物的制备
JP5001842B2 (ja) 2004-09-14 2012-08-15 ギリアド ファーマセット エルエルシー ２’−フルオロ−２’−アルキル−置換又は他の置換されていてもよいリボフラノシルピリミジン類及びプリン類並びにそれらの誘導体の製造
TWI437990B (zh) * 2004-10-29 2014-05-21 Vertex Pharma Vx-950之醫藥用途
EP1976516B9 (en) 2006-01-09 2013-10-30 Romark Laboratories, L.C. Viral hepatitis treatment
US7964580B2 (en) 2007-03-30 2011-06-21 Pharmasset, Inc. Nucleoside phosphoramidate prodrugs
CN101820887A (zh) 2007-07-25 2010-09-01 拜奥雷克斯治疗公司 干扰素控释药品以及使用相同药品治疗hcv感染
TW200946541A (en) 2008-03-27 2009-11-16 Idenix Pharmaceuticals Inc Solid forms of an anti-HIV phosphoindole compound
RU2369403C1 (ru) * 2008-05-22 2009-10-10 Сергей Юрьевич Родионов Способ лечения хронических вирусных гепатитов
CL2009002207A1 (es) 2008-12-23 2011-02-18 Gilead Pharmasset Llc Compuestos derivados de 3-hidroxi-5-(9h-purin-9-il)tetrahidrofuran-2-il, inhibidor de la replicacion de arn viral dependiente de arn; composicion farmaceutica; uso para el tratamiento de hepatitis c.
CL2009002208A1 (es) 2008-12-23 2010-10-29 Gilead Pharmasset Llc Un compuesto (2s)-2-((((2r,3r,4r,5r)-5-(2-amino-6-etoxi-9h-purin-9-il)-4-fluoro-3-hidroxi-4-metiltetrahidrofuran-2-il)metoxi)(hidroxi)fosforilamino)propanoico, inhibidores de la replicacion de arn viral; composicion farmaceutica; y su uso en el tratamiento de infeccion por hepatitis c, virus del nilo occidental, entre otras.
KR20110104074A (ko) 2008-12-23 2011-09-21 파마셋 인코포레이티드 퓨린 뉴클레오시드의 합성
WO2010129947A2 (en) 2009-05-08 2010-11-11 Sciclone Pharmaceuticals, Inc. Alpha thymosin peptides as vaccine enhancers
TWI583692B (zh) 2009-05-20 2017-05-21 基利法瑪席特有限責任公司 核苷磷醯胺
US8618076B2 (en) 2009-05-20 2013-12-31 Gilead Pharmasset Llc Nucleoside phosphoramidates
MX2012011171A (es) 2010-03-31 2013-02-01 Gilead Pharmasset Llc Fosforamidatos de nucleosido.
KR20140035305A (ko) * 2010-10-05 2014-03-21 노파르티스 아게 C형 간염 바이러스 감염의 새로운 치료법
AU2011336632B2 (en) 2010-11-30 2015-09-03 Gilead Pharmasset Llc Compounds
EA201391262A1 (ru) * 2011-03-02 2014-03-31 Джером Шентаг Композиция, способ лечения и диагностики стеатоза печени как самостоятельного заболевания или в комбинации с инфекцией гепатита с
AP2014007575A0 (en) 2011-09-16 2012-04-30 Gilead Pharmasset Llc Methods for treating HCV
US8889159B2 (en) 2011-11-29 2014-11-18 Gilead Pharmasset Llc Compositions and methods for treating hepatitis C virus
SG11201506021XA (en) 2013-01-31 2015-08-28 Gilead Pharmasset Llc Combination formulation of two antiviral compounds
JP2016529293A (ja) 2013-08-27 2016-09-23 ギリアド ファーマセット エルエルシー ２つの抗ウイルス化合物の組合せ製剤

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4211771A (en) 1971-06-01 1980-07-08 Robins Ronald K Treatment of human viral diseases with 1-B-D-ribofuranosyl-1,2,4-triazole-3-carboxamide
US4530901A (en) 1980-01-08 1985-07-23 Biogen N.V. Recombinant DNA molecules and their use in producing human interferon-like polypeptides
US6936694B1 (en) 1982-05-06 2005-08-30 Intermune, Inc. Manufacture and expression of large structural genes
US4492537A (en) 1982-12-10 1985-01-08 Awerkamp John B Fluid-operated oil or water well pump
US4917888A (en) 1985-06-26 1990-04-17 Cetus Corporation Solubilization of immunotoxins for pharmaceutical compositions using polymer conjugation
US4766106A (en) 1985-06-26 1988-08-23 Cetus Corporation Solubilization of proteins for pharmaceutical compositions using polymer conjugation
JP2514950B2 (ja) 1986-03-10 1996-07-10 エフ・ホフマン―ラ ロシユ アーゲー 化学修飾蛋白質，その製造法および中間体
US5595732A (en) 1991-03-25 1997-01-21 Hoffmann-La Roche Inc. Polyethylene-protein conjugates
US5382657A (en) 1992-08-26 1995-01-17 Hoffmann-La Roche Inc. Peg-interferon conjugates
KR960705579A (ko) 1993-11-10 1996-11-08 에릭에스. 딕커 개선된 인터페론 중합체 결합체(Improved interferon polymer conjugates)
US5766582A (en) 1994-10-11 1998-06-16 Schering Corporation Stable, aqueous alfa interferon solution formulations
US5824784A (en) * 1994-10-12 1998-10-20 Amgen Inc. N-terminally chemically modified protein compositions and methods
TW426523B (en) 1995-04-06 2001-03-21 Hoffmann La Roche Interferon solution
US6387365B1 (en) * 1995-05-19 2002-05-14 Schering Corporation Combination therapy for chronic hepatitis C infection
US5908621A (en) * 1995-11-02 1999-06-01 Schering Corporation Polyethylene glycol modified interferon therapy
JP2000507917A (ja) * 1995-11-02 2000-06-27 シェーリング コーポレイション 持続的低用量サイトカイン注入治療
TW517067B (en) 1996-05-31 2003-01-11 Hoffmann La Roche Interferon conjugates
EP1011743B1 (en) 1997-08-13 2011-07-27 Boston Scientific Limited Loading and release of water-insoluble drugs
EP1317929A3 (en) * 1997-09-21 2003-07-02 Schering Corporation Combination therapy for eradicating detectable HCV-RNA in patients having chronic hepatitis c infection

Also Published As

Publication number Publication date
JP2002515453A (ja) 2002-05-28
AU2005220271B9 (en) 2010-12-09
CN1309568A (zh) 2001-08-22
HUP0103423A3 (en) 2003-11-28
NZ507621A (en) 2002-11-26
HK1021131A1 (en) 2000-06-02
EP1213029A1 (en) 2002-06-12
EP2305287A1 (en) 2011-04-06
SK17102000A3 (sk) 2001-05-10
AU2005220271B8 (en) 2010-11-18
DE69901321T2 (de) 2002-12-12
IL139220A0 (en) 2001-11-25
ES2172288T3 (es) 2002-09-16
CZ20004177A3 (cs) 2001-04-11
NO330715B1 (no) 2011-06-20
NO20005755D0 (no) 2000-11-14
JP5281726B2 (ja) 2013-09-04
AU766597B2 (en) 2003-10-16
TWI277424B (en) 2007-04-01
HU230432B1 (hu) 2016-06-28
AR019551A1 (es) 2002-02-27
CZ300540B6 (cs) 2009-06-10
IL207259A0 (en) 2010-12-30
DE69901321D1 (de) 2002-05-29
IL139220A (en) 2013-02-28
WO1999059621A1 (en) 1999-11-25
JP2011173898A (ja) 2011-09-08
NO20005755L (no) 2001-01-12
PT956861E (pt) 2002-08-30
KR100694345B1 (ko) 2007-03-12
DK0956861T3 (da) 2002-07-01
HUP0103423A2 (hu) 2002-01-28
ATE216591T1 (de) 2002-05-15
MY129244A (en) 2007-03-30
AU2005220271A1 (en) 2005-11-03
CN1230198C (zh) 2005-12-07
AU2005220271B2 (en) 2005-11-03
CA2331823A1 (en) 1999-11-25
SK288038B6 (en) 2013-01-02
EP0956861A1 (en) 1999-11-17
AU3860099A (en) 1999-12-06
EP0956861B1 (en) 2002-04-24
KR20010043624A (ko) 2001-05-25
IL207259A (en) 2016-08-31

Similar Documents

Publication Publication Date Title
BR9910505A (pt) Terapia de combinação compreendendo ribavirina e interferon alfa em pacientes cândidos de tratamento antiviral tendo infecção crÈnica por hepatite c
CO4970691A1 (es) Terapia en combinacion para erradicar vhc-arn detectable en pacientes que padecen infeccion de hepatitis c cronica
BR0114636A (pt) Terapia combinada para hcv de interferon-alfa peguilado/ribavirina
BR9911076A (pt) Uso de peg-ifn-alfa e ribavirina para o tratamento de hepatite c crÈnica
WO2000037110A3 (en) Ribavirin-pegylated interferon alfa induction hcv combination therapy
AR021226A1 (es) Terapia combinatoria con ribavirina-interferon alfa para erradicar el hcv-rna detectable en aquellos pacientes que presentan infeccion porhepatitis c cronica
BR9915546A (pt) Terapia de combinação de ribavirin- interferon alfa para a erradiação de hcv-rna detectável em pacientes tendo infecção por hepatite c crÈnica
BR0010593A (pt) Terapia de combinação com antagonista de ccr5-interferon alfa peguilado para hiv
RS20120201A3 (en) METHODS AND MIXTURES FOR TREATMENT OF VIRAL HEPATITIS C
BR0009840A (pt) Terapia de combinação para hcv, contendo ribavirina em associação com antioxidantes
PE20001386A1 (es) Terapia de combinacion para el vhc por induccion de ribavirina-interferon alfa
BR0108997A (pt) Terapia imune adjuvante para hiv
BRPI0409711A (pt) tratamento ou prevenção de infecções respiratórias virais com peptìdeos da alfa timosina
DK1143976T3 (da) Beta-D-2', 3'-didehydro-2', 3'-dideoxy-5-fluorcytidin til anvendelse i behandlingen af HIV-infektioner
BR0113115A (pt) Tratamento de hepatite c com timosina, interferon e ribavirina
ECSP982669A (es) Terapia en combinacion para erradicar vhc -arn detectable en pacientes que padecen infeccion de hetatitis c cronica
ECSP993178A (es) Terapia combinatoria con ribarvirina -interferon alfa para erradicar el hcv - rna detectable en aquellos pacientes que presentan infeccion por hepatitis c cronica
AR013424A1 (es) Uso de uridina para la preparacion de una composicion farmaceutica util para inhibir la toxicidad de los analogos de pirimidina
EP1731155A3 (en) Beta-d-2', 3' -didehydro-2', 3' -dideoxy-5-fluorocytidine for use in the treatment of hiv infections

Legal Events

Date Code Title Description
B07A Application suspended after technical examination (opinion) [chapter 7.1 patent gazette]
B09B Patent application refused [chapter 9.2 patent gazette]

Free format text: INDEFIRO O PEDIDO DE ACORDO COM O(S) ARTIGO(S) 37, 8O, 13, 10 DA LPI

B09B Patent application refused [chapter 9.2 patent gazette]

Free format text: MANTIDO O INDEFERIMENTO UMA VEZ QUE NAO FOI APRESENTADO RECURSO DENTRO DO PRAZO LEGAL.